Nonalcoholic fatty liver disease, widely known as NAFLD, is the most common chronic liver condition worldwide, affecting roughly 30% of the global population. It refers to a buildup of excess fat in liver cells that is not caused by heavy alcohol use. Most people with NAFLD have no symptoms and may never know they have it, but a significant minority progress to liver inflammation, scarring, and potentially life-threatening complications. The condition is so tightly woven into the metabolic health crisis that the medical community recently voted to rename it entirely.
Why the Name Is Changing
In 2023, a large international consensus effort proposed replacing “NAFLD” with “metabolic dysfunction-associated steatotic liver disease,” or MASLD. The change reflects two goals: to better describe what the disease actually is, and to remove the word “nonalcoholic,” which many patients and clinicians found stigmatizing and misleading. Rather than defining the disease by what it is not (not caused by alcohol), the new name anchors it to what it is: a metabolic problem involving fat in the liver alongside at least one cardiometabolic risk factor such as obesity, elevated blood sugar, or abnormal cholesterol.1PubMed Central. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease You will see both names in medical literature and clinical settings for years, so understanding them as the same condition under different labels is useful.
A Global Epidemic in Plain Sight
A systematic review covering studies from 1990 to 2019 found that the overall global prevalence of NAFLD was about 30%, and that this figure had climbed sharply over time, from roughly 25% in the earliest study period to 38% in the most recent one.2PubMed Central. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review That increase of more than 50% in under three decades mirrors the global rise in obesity and type 2 diabetes.
Rates vary considerably by region. Latin America has the highest estimated prevalence at around 44%, followed by the Middle East and North Africa at roughly 37%. South Asia, Southeast Asia, and North America cluster between 31% and 34%, while Western Europe sits near 25%.3PubMed Central. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review Among people who are already overweight or obese, the numbers jump dramatically: about 70% of overweight individuals and 75% of obese individuals have NAFLD, according to a meta-analysis of over 100,000 people.4The Lancet Gastroenterology & Hepatology. Global prevalence of non-alcoholic fatty liver disease in overweight and obese patients: a systematic review and meta-analysis
What Happens Inside the Liver
NAFLD starts when the liver accumulates more fat than it can process. In most cases, the root problem is insulin resistance. When fat tissue stops responding properly to insulin, it releases a flood of free fatty acids into the bloodstream. The liver absorbs these fatty acids, but when the supply chronically outpaces its ability to burn or export them, the excess gets stored as fat droplets inside liver cells.5PubMed. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis At this stage, the condition is called simple steatosis and is considered relatively benign.
The trouble begins when the fat itself becomes toxic. Free fatty acids that cannot be safely stored get shunted into harmful metabolic pathways, producing byproducts that damage liver cells from the inside.6PubMed. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis This lipotoxicity triggers inflammation, and the liver’s resident immune cells amplify the response. When inflammation becomes persistent, the diagnosis shifts from simple fatty liver to nonalcoholic steatohepatitis, or NASH, which carries a meaningful risk of progressive scarring.7PubMed Central. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma Roughly 10 to 20% of people with NAFLD develop NASH.
Fructose and the Modern Diet
Diet plays a central role, and fructose stands out as a particularly potent contributor. The liver is the main organ responsible for metabolizing fructose, and it processes the sugar through pathways that aggressively promote new fat production, a process called de novo lipogenesis. Both human and animal research shows that fructose drives this fat-making machinery more strongly than glucose does.8PubMed Central. Fructose drives de novo lipogenesis affecting metabolic health
Several features of fructose metabolism make it especially problematic. Fructose arrives at the liver in high concentrations through the portal vein before other tissues get a chance to use it. It ramps up the enzymes that build fat even when the body is already insulin resistant, because fructose metabolism does not require insulin. It also depletes energy stores within liver cells and suppresses the burning of existing fat, creating a double hit.9PubMed Central. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease A controlled trial quantified this effect: people who drank fructose-sweetened or sucrose-sweetened beverages daily for several weeks saw their liver’s rate of new fat production roughly double compared to a control group.10PubMed. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial Glucose-sweetened drinks did not produce the same effect, which gives real-world weight to the advice about limiting sugary beverages, particularly those sweetened with high-fructose corn syrup or table sugar.
Genetic Susceptibility and Ancestry Differences
Not everyone with the same diet and body weight develops NAFLD, and genetics helps explain why. The best-studied gene variant is in PNPLA3. A specific version of this gene (the I148M variant) was strongly associated with increased liver fat and liver inflammation in a landmark study. People who carry two copies of the risk allele had liver fat levels more than twice as high as noncarriers.11Nature Genetics. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
This variant is most common in Hispanic populations, the group with the highest NAFLD rates worldwide, and least common in people of African descent, who have lower rates of the disease even at comparable levels of obesity. A separate protective allele in the same gene was identified in African Americans and linked to lower liver fat levels.12Nature Genetics. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Another gene, TM6SF2, has been identified as a potential master regulator that influences not just liver disease risk but also cardiovascular outcomes, essentially tipping the balance of metabolic damage between the liver and the blood vessels.13PubMed. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 Genetic testing for these variants is not yet part of routine clinical practice, but it helps explain why NAFLD runs in families and hits certain populations disproportionately.
You Do Not Have to Be Overweight
One of the most common misconceptions about NAFLD is that it only affects people who are visibly overweight. In reality, an estimated 10 to 20% of people with NAFLD are lean, meaning their body mass index falls below the standard overweight threshold.14Biomedicine & Pharmacotherapy. Review Recent advances in lean NAFLD Lean NAFLD appears to be driven more heavily by genetic susceptibility, epigenetic changes, and environmental exposures rather than excess calorie intake alone.
People with lean NAFLD tend to have fewer of the classic metabolic risk factors like diabetes and high blood pressure compared to their overweight counterparts. But the disease is far from harmless in this group. In advanced stages, lean individuals with NAFLD have been found to have higher fibrosis scores and greater rates of cardiovascular problems and overall mortality.15Biomedicine & Pharmacotherapy. Review Recent advances in lean NAFLD A global meta-analysis also documented that metabolic complications like central obesity and abnormal cholesterol are not absent in lean NAFLD; they are simply less prevalent than in the obese NAFLD population, not nonexistent.16PubMed. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis The practical takeaway is that a normal number on the scale does not guarantee a healthy liver, especially if other metabolic warning signs are present.
From Fat to Fibrosis to Cancer
The disease spectrum runs from simple fat accumulation through inflammation (NASH) to fibrosis, cirrhosis, and ultimately liver cancer. Inflammation is considered the engine of progression.17PubMed Central. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma When liver cells are repeatedly damaged, a specific cell type called the hepatic stellate cell activates and begins producing collagen, the structural protein that forms scar tissue. Over time, these cells transform the liver’s soft, functional tissue into stiff, fibrous bands that distort the organ’s blood flow and raise pressure in the portal vein system.18PubMed Central. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets19PubMed. Hepatic stellate cells and liver fibrosis
What makes this clinically worrying is that liver cancer can develop even in people with NAFLD who have not progressed to full cirrhosis. The chronic inflammatory and insulin-resistant environment itself appears to promote tumor formation.20PubMed Central. Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival This is different from the traditional understanding that liver cancer follows a neat staircase from cirrhosis. The fact that NAFLD-related cancer can appear at earlier fibrosis stages means surveillance strategies originally designed for cirrhotic patients may miss some cases.
Cardiovascular Risk and Beyond-the-Liver Effects
NAFLD is not purely a liver problem. The same metabolic dysfunction that fills the liver with fat also promotes atherosclerosis, the buildup of plaque inside arteries. Cardiovascular events are actually a leading cause of death in people with NAFLD, and the condition has been described as an independent risk factor for atherosclerotic cardiovascular disease.21A Comprehensive Guide to Non-alcoholic Fatty Liver Disease. Non-alcoholic-Related Fatty Liver Disease (NAFLD) as a Risk Factor for Atherosclerotic Cardiovascular Disease The relationship between liver fat and heart disease is complex, though. A meta-analysis found that while cardiovascular events are common in NAFLD patients, the statistical association between NAFLD and death specifically from cardiovascular disease was not clearly significant after pooling the available studies.22Scientific Reports. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis That does not mean the heart risk is imaginary; it likely means that shared risk factors like obesity and diabetes make it hard to isolate the liver’s independent contribution in population-level data.
How It Gets Diagnosed
Most people with NAFLD are diagnosed incidentally, often when an ultrasound or blood test done for another reason reveals something unexpected. Liver biopsy remains the gold standard for grading inflammation and staging fibrosis, but it is invasive, expensive, and impractical for screening a condition that affects nearly a third of adults. This has driven a push toward non-invasive alternatives.
Blood-based scoring systems and imaging-based tools each have strengths and limitations. Vibration-controlled transient elastography, a specialized ultrasound technique that measures liver stiffness, has been shown to be more accurate than blood tests alone for detecting advanced fibrosis.23PubMed. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD Combining blood markers with elastography in a sequential algorithm can achieve diagnostic accuracy around 90% for advanced fibrosis, while limiting the need for liver biopsy to roughly one in five patients.24PubMed. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD Another blood-based tool, the Enhanced Liver Fibrosis test, performs well at ruling out fibrosis at lower cutoff thresholds but requires very high thresholds to reliably confirm it, which reduces its sensitivity.25PubMed. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis In practice, clinicians often use a simple, inexpensive blood test as a first screen and reserve the more specialized tools for people whose initial results fall into an uncertain range.
Weight Loss Remains the Most Proven Treatment
No amount of supplements or trendy liver cleanses has solid evidence behind it for NAFLD. What does have evidence is losing weight. The thresholds are fairly clear. A study of patients with biopsy-confirmed NASH found that 58% of those who lost at least 5% of their body weight achieved resolution of NASH, while 82% saw meaningful improvement on standardized liver scores. Among those who lost 10% or more, 90% had NASH resolution and 45% had regression of fibrosis.26PubMed. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Fibrosis regression, which is the harder outcome to achieve, appears to require more substantial weight loss. A separate study found that about 63% of patients who lost at least 10% of their total body weight saw their fibrosis improve, compared to just 9% of those who lost less.27PubMed. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis The method of weight loss, whether through diet and exercise or bariatric surgery, mattered less than the magnitude of the loss itself. This is encouraging in principle but challenging in practice, since losing 10% of body weight and keeping it off is something most people struggle to sustain.
On the pharmaceutical side, the landscape is evolving. Resmetirom, a thyroid hormone receptor agonist, became the first drug approved specifically for NASH with liver fibrosis. In its pivotal trial, about 26 to 30% of treated patients achieved NASH resolution without worsening fibrosis, compared to roughly 10% on placebo. Around 25% saw their fibrosis improve by at least one stage, versus about 15% on placebo.28Nature. Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Those numbers may sound modest, but in a disease where the only prior treatment was “lose weight,” a drug that reproducibly reverses fibrosis in a quarter of patients represents a genuine shift.
NAFLD in Children
NAFLD is no longer an adult disease. Childhood obesity has brought fatty liver into pediatric clinics, and the disease looks somewhat different in younger patients. Children tend to show a distinct pattern of liver damage: more fat accumulation and more inflammation around the portal areas of the liver, but less of the type of inflammation and scarring that predominates in adults.29PubMed Central. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis This pediatric pattern, sometimes called type 2 NASH, has been found in over half of children with NAFLD in some studies.30PubMed Central. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology
The concern with pediatric NAFLD extends beyond the liver itself. A child diagnosed at age 10 faces decades of potential disease progression. And because children’s livers respond to metabolic insults differently than adult livers do, treatments developed in adult populations cannot simply be scaled down and applied to kids. Screening, diagnosis, and management guidelines for pediatric NAFLD remain less well established than their adult counterparts, leaving many families navigating the condition with limited clinical guidance.
The Gut Connection
The liver receives blood directly from the intestines through the portal vein, which means it is constantly exposed to whatever gets through the gut wall. In a healthy gut, the intestinal lining acts as a selective barrier. In NAFLD, that barrier often breaks down. This “leaky gut” allows bacterial products, especially endotoxins from certain bacteria, to reach the liver in higher concentrations than normal and trigger inflammatory responses.31PubMed Central. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
Adding another layer, people with NAFLD tend to harbor an altered mix of gut bacteria, including increased numbers of species that produce ethanol as a metabolic byproduct. This means the liver of someone with NAFLD may be dealing with a low-level alcohol exposure generated internally, even if the person never drinks.32PubMed Central. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target Research into whether restoring gut barrier integrity or rebalancing the microbiome can slow NAFLD progression is still in its early stages, but the gut-liver axis has become one of the more active areas of investigation.
Less Obvious Risk Factors
Beyond diet, weight, and genetics, several less intuitive factors contribute to NAFLD risk. Shift work and chronic sleep disruption are one. The liver’s metabolic activity follows a circadian rhythm, and forcing it to operate out of sync through night shifts or irregular sleep schedules disrupts fat metabolism and promotes fat accumulation. Studies have linked night shift work to elevated liver enzymes and potentially faster progression from simple fatty liver to NASH.33PubMed Central. Night shift-induced circadian disruption: links to initiation of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and risk of hepatic cancer
Environmental chemicals also deserve attention. Endocrine-disrupting chemicals, found in plastics, pesticides, and industrial pollutants, can interfere with hormone receptors in the liver and alter how genes involved in fat metabolism are expressed. Experimental research has identified several pathways through which these chemicals could initiate or worsen fatty liver disease.34PubMed Central. Endocrine-disrupting chemicals and fatty liver disease While it is difficult to isolate the effect of any single chemical exposure in human populations, the cumulative load of environmental toxins is increasingly recognized as a relevant piece of the NAFLD puzzle.
Food insecurity adds a socioeconomic dimension. In wealthier countries, people facing the highest levels of food insecurity had significantly higher rates of NAFLD compared to those with reliable food access. Interestingly, the pattern reversed in lower-income countries, where food insecurity was associated with lower NAFLD prevalence, likely because it still manifests as caloric deficiency rather than reliance on cheap, calorie-dense processed food.35PubMed. Association of food insecurity with MASLD prevalence and liver-related mortality This finding underscores that NAFLD is as much a disease of food quality and economic access as it is of personal dietary choices.
An Evolutionary Mismatch
Some researchers frame NAFLD as a consequence of evolutionary biology colliding with modern life. The “thrifty gene” hypothesis, first proposed in the 1960s, suggests that mutations beneficial during periods of famine, when efficiently storing energy as fat meant survival, now predispose us to obesity and metabolic disease in an environment of constant caloric abundance. One version of this hypothesis focuses on the loss of the uricase gene in human ancestors, which raised uric acid levels and may have enhanced the body’s ability to convert fructose into fat stores.36PubMed Central. Do thrifty genes exist? Revisiting uricase Whether or not every detail of this hypothesis holds up, the broader point resonates: the human liver evolved to stockpile energy for lean times. In a world where those lean times rarely come, the same machinery fills the liver with fat it never gets the signal to burn.